and equinoxes. In this way, we might test the influence of the increasing (February–April) or decreasing (August–October) photoperiod, and insufficient (November–January) or excessive (May–July) daylight.

Since Partonen & Lonnqvist do not report monthly frequencies, we cannot apply these criteria to the Finnish data. However, we have applied them to a Portuguese sample of 34 longitudinally followed bipolar patients (Pio-Abreu & Pires, 1985), and to 178 female admissions for mania and depression (Boto et al., 1991). Both studies revealed a peak of bipolar episodes during the equinoctial periods, where depressions predominated from February to April, and manias between August and October. In contrast, mixed and switching episodes, as well as some unipolar depressions, tended to occur around the solstices.

Although these results are consistent with an extensive review by Wehr & Rosenthal (1989), they may be idiosyncratic to Portugal. Since sunshine varies with latitude, more studies are needed worldwide in order to understand the problem better. However, it would be preferable if results were presented in terms of monthly frequencies, and not simply as the required figures for testing seasonality as conventionally defined.


J. L. Pio-Abreu Psychiatric Clinic, University Hospital of Coimbra, 3049 Coimbra, Portugal.

Terminology of learning disability

Sir: Few would disagree with Reid (1997) that learning disability is not an ideal term. It may also be true that it was adopted by the Royal College of Psychiatrists simply for the sake of political correctness. This, however, even when coupled with the objection that the term contains no medical or psychiatric dimension, provides no adequate grounds for yet a further unwelcome change in terminology.

Mental handicap, the term generally discarded in the UK but nevertheless still favoured by Dr Reid and many others, remains less appropriate than learning disability for two important reasons. The first is, as Reid himself points out, because of the objections of those suffering from the condition and able to express an opinion. The second is the difficulty experienced by the general public in distinguishing between mental handicap and mental illness, largely because of the use of the word ‘mental’. Not surprisingly, this confusion led to the assumption that mental handicap was primarily a medical problem. If now, instead, it is thought that the term learning disability implies that the condition is essentially educational, rather than register dismay we should instead throw our hats in the air. This description does offer, at all contain a greater element of truth.

The problems of people with learning disability can be met only by a multidisciplinary approach. It is unlikely that the emphasis on the word ‘learning’ can diminish the contribution of medicine, particularly psychiatry, to the care of this group.


Gwyn Howells Belvedere House, Fort George, St Peter Port, Guernsey GY1 2SJ.

Valproate and neuroleptic medication

Sir: Barnes et al (1996) point out the paucity of data on adjunctive use of valproate in the treatment of psychotic disorders only partially responsive to neuroleptics. We have conducted an open trial of 17 out-patients (six male; mean age 34; s.d. 10 years) to ascertain whether valproate can be used to ‘spare’ neuroleptics in patients with bipolar disorder with psychosis (n=13) and schizoaffective disorder (n=5). All patients had been stabilised on neuroleptics for at least six months. Mean pre-valproate neuroleptic dose was 260 mg chlorpromazine equivalents per day (s.d. 150 mg; range 25–500). In the six months post-valproate, only two patients required ongoing neuroleptics, with doses of 100 and 200 mg chlorpromazine equivalents daily (prior doses 200 and 500 mg, respectively).

This preliminary study, with the methodological limitations inherent in open, non-randomised, non-blind designs, nevertheless raises the possibility of wider use of valproate to spare neuroleptics in patients with bipolar and schizoaffective disorders, and potentially schizophrenia as well (three further treatment-resistant schizophrenia patients have been commenced on valproate...
with promising clinical improvement). We are currently engaged in a study to pursue this issue in a more scientific manner, and welcome the views of other clinicians.


S. Rentens, D. Castle Mills Street Clinical Research Unit, 35 Mills Street, Bentley, WA 6102, Western Australia

Genetic polymorphism and drug-induced movement disorders

Sir: We were interested to read the paper by Armstrong et al (1997) on drug-induced movement disorders in relation to the CYP2D6 genotype. We would agree that this important polymorphism may well be a contributory factor in more chronic drug-induced movement disorders.

Several lines of evidence support this. Firstly, one of the most robust findings in the whole field of tardive dyskinesia (TD) research is the link between TD and high neuroleptic dosage. Impaired clearance of antipsychotics due to the poor metaboliser genotype leads to elevated plasma levels, which has clear implications in view of the first association. Other studies have attempted to assess the problem from a different standpoint: looking at the variation in neuroleptic breakdown between those with TD and schizophrenic controls. The best study in this area is that of Yesavage et al (1987), which found a significant difference in standardised thioxanthine levels between 21 TD sufferers and 20 controls.

In our recent study (Bates, 1997) we used promethazine, a phenothiazine predominantly metabolised by the CYP2D6 cytochrome, to probe metabolic clearance in 18 patients, 10 with TD and eight controls. We used a high-performance liquid chromatography technique which simultaneously assayed promethazine and its two major breakdown products, the sulphoxide and monodesmethyl metabolites. We found evidence of significant impairment of metabolism of promethazine in the TD group, with raised promethazine levels and raised promethazine to metabolite ratios, indicating this was not an effect of varying absorption or bioavailability. We will be publishing our results more fully soon.

This simple and relatively inexpensive method may prove useful in pretreatment testing to enable prediction of those likely to develop TD or concentration-dependent side-effects, and to guide dosage decisions.


G. D. L. Bates Birmingham Children's Hospital, Ladywood Middleway, Ladywood, Birmingham B16 8ET A. E. van Woerkom, O. Lopes Queen Elizabeth Psychiatric Hospital, Mindelsohn Way, Birmingham B15 2TZ R. Waring, L. Klovorz University of Birmingham, Edgbaston, Birmingham

Demography and age at onset of schizophrenia

Sir: Jablensky & Cole (1997) conclude from their analysis of the WHO 10-Country study of schizophrenia that marital status has a major effect on age at onset of schizophrenia, and that the effect of gender disappears when controlling for marital status (and other variables). However, these findings are partly due to demographic effects. To explain this artefact assume that outbreak of schizophrenia occurs (like a random event) irrespective of marital status. As is well known, married people are in our population on average older than single ones. Therefore the mean age at onset of schizophrenia will be later for married people than for single ones. This difference does not reflect a real association between schizophrenia and marriage (which was excluded by the hypothetical model) but it reflects a trivial demographic effect due to the different age structures of married and single people. This applies to men and women in a different way. In general, women marry earlier than men. Thus, in the population, married women are on average younger than married men, and unmarried women are younger than unmarried men. Let us assume that outbreak of schizophrenia is related neither to gender nor to marital status. Then because of these different age structures the mean age at onset will be earlier for married women than for married men. The same relation holds for singles. But, as above, these differences are due to a trivial demographic effect. If there is a real association between gender and schizophrenia in the sense that onset is later for women, then this difference is reduced when comparing married women with married men and single women with single men. Thus differences in the age structures between married and single persons in the population explain, at least in part, the effects of marital status and gender on age at onset, described by Jablensky & Cole. The differences in age at onset between developing and developed countries may be attributed to different demographic structures in these countries. We do not deny these effects, but to disentangle demographic effects from real effects the age structures of the underlying population must be taken into account when analysing the data.


C. Jannen-Stanmetz, W. Löffler, H. Häfner Central Institute of Mental Health, J 5, 68159 Mannheim, Germany

Author's reply: Jannen-Steinmetz et al suggest that "differences in the age structures between married and single persons . . . explain, at least in part, the effects of marital status and gender on age at onset, described by Jablensky & Cole". Since the statistical analyses we use uncorrelate gender and marital status prior to examining the relationship of either variable to age at onset, Steinmetz et al, can rest assured that no part of our conclusions reflects a spurious correlation between marital status and age at onset of schizophrenia that is induced by those two variables' common association with gender differences in age at marriage.

In the general linear model, the effects of gender (and gender-correlated differences in age at marriage) are partialled out, or controlled for, in the calculus underlying multiple regression (Mosteller & Tukey,